Loading...

Home
ETF
INKT

INKT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

INKT News

C-Further Advances Pediatric Cancer Therapeutics Initiatives

15h agoNewsfilter

MiNK Therapeutics Secures $1.1 Million Funding for Pediatric Cancer Collaboration

11h agoBenzinga

MiNK Therapeutics Partners with C-Further for Pediatric Oncology

13h agoNASDAQ.COM

MiNK Therapeutics Stock Soars 60% on Key Collaboration with C-Further

14h agoseekingalpha

MiNK Therapeutics Collaborates with C-Further on Pediatric Cancer Cell Therapy

14h agostocktwits

MiNK Therapeutics Partners with C-Further to Develop Pediatric Cancer Therapy

15h agoNewsfilter

MiNK Therapeutics Unveils New Insights on iNKT Cells in IPF

Feb 04 2026Newsfilter

MiNK Therapeutics Initiates GvHD Clinical Trial for agenT-797 Therapy

Jan 08 2026Globenewswire

Ryvyl Inc Announces 1-for-35 Reverse Split, Shares Plunge 14.4%

Dec 30 2025Benzinga

Fonar Corp (FONR) Signs Definitive Agreement for Take-Private Sale, Shares Surge 24.5%

Dec 30 2025Benzinga

MiNK Therapeutics Reveals New Findings Indicating MiNK-215 Exhibits Strong Anti-Tumor Effects in Treatment-Resistant Solid Tumors

Nov 20 2025Newsfilter

Earnings Report Ahead of Market Opening for November 14, 2025: SR, SRRK, TWST, BTBT, SGML, FRGE, SBC, GAUZ, INKT, MRSN, ITRM, LMFA

Nov 13 2025NASDAQ.COM

MiNK Therapeutics Announces Lasting Responses and Immune Activation from Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 07 2025Newsfilter

MiNK Therapeutics to Announce Q3 2025 Financial Results and Showcase Key Clinical and Corporate Achievements Advancing iNKT Platform Towards Critical Development

Nov 05 2025Newsfilter

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14 2025Newsfilter

MiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnerships

Aug 14 2025SeekingAlpha